| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T38 |
0-80 |
Sentence |
denotes |
FcγR‐mediated mechanism of action Effector responses Action Dominant receptor |
| T39 |
81-179 |
Sentence |
denotes |
Activation Antibody‐dependent cell‐mediated cytotoxicity Direct killing of target cell FcγRIIIa |
| T40 |
180-296 |
Sentence |
denotes |
Antibody‐dependent cell‐mediated phagocytosis, trogocytosis Direct killing of target cell FcγRIIIa, FcγRIIa, FcγRI |
| T41 |
297-383 |
Sentence |
denotes |
Antigen presentation Vaccine‐like immunity post‐mAb therapy FcγRIIa, FcγRI, FcγRIIIa |
| T42 |
384-568 |
Sentence |
denotes |
Inhibition Reduce B‐cell proliferation or innate cell activation by antibody complexes Inhibition of ITAM cell activation (i.e. BCR) or activating‐type FcR (i.e. FcγR, FcεRI, FcαRI). |
| T43 |
569-649 |
Sentence |
denotes |
Note that the FcγRIIb must be co‐cross‐linked with the ITAM activating receptor. |
| T44 |
651-658 |
Sentence |
denotes |
FcγRIIb |
| T45 |
659-730 |
Sentence |
denotes |
Sweeping Internalization Removal of small immune complexes FcγRIIb a |
| T46 |
731-925 |
Sentence |
denotes |
Scaffolding Target agonism or apoptosis Passive “super‐cross‐linking” of mAb on opsonized target cell, for example, CD40, CD28, CD20, by FcγR on an adjacent cell FcγRIIb; also FcγRIIa, FcγRI? |
